Other
Capillary Malformation
3
Pipeline Programs↗
1
Active Trials↗
1
Companies Involved↗
Capillary Malformation is an early-stage landscape with 3 programs across 1 company. The most active players are Novartis. 1 therapy is approved.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical
No programs
Phase 1
No programs
Phase 3
No programs
Approved1
Analysis
Trial Status
3
clinical trials
Unknown status1 · 33%
Terminated1 · 33%
Recruiting1 · 33%
Clinical Trials
Trial Activity
Electrosclerotherapy for Capillary Malformations
Unknown status·—·Phase 2·NCT02883023·20 enrolled
Assessment of the Efficacy and Safety of Alpelisib (BYL719) in Pediatric and Adult Patients With Megalencephaly-CApillary Malformation Polymicrogyria Syndrome (MCAP)
Recruiting·—·Phase 2·NCT05577754·20 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)